Oseltamivir

Excreted Unchanged %
99
Half-Life (Normalesrd) Hours
6-10/>20
Plasma Protein Binding %
3
Volume Of Distribution L/Kg
0.3-0.4
Dose For Normal Renal Function
75 mg bid for treatment; qd for prophylaxis
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100 [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
qd (treatment); qod (prophylaxis) [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
See notes [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: See notes, [B]
Supplement For Dialysis [Recommendation Level]: Pd
PD: See notes, [B]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 100%, [D]
References
He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999; 37: 471-84. [PMID: 10628898]
Toxicity Notes
Can use full doses for CrCl >30 mL/min. For CrCl <30 mL/min, pharmacokinetic parameters for 75 mg qod predict adequate concentrations for treatment but efficacy not tested. For PD, 30 mg weekly or twice weekly predicts adequate concentrations but efficacy not tested. For HD, 30 mg on nondialysis days predicts adequate concentrations for treatment but efficacy not tested. Drug has a wide safety margin so appears to be little risk of higher-than-usual concentrations in renal failure.